Patologia: Melanoma, Neoplasie del polmone, Altre neoplasie
Fase di studio: III
Richiesta mandatoria di tessuto: No
Linee di trattamento: Non applicabile
Criteri di inclusione:
- Advanced unresectable or metastatic tumor(s)
- Currently enrolled in a Merck-sponsored pembrolizumab study and is receiving study treatment or in a Follow-up Phase at the time MK-3475-587 is open. The parent studies must have completed all regulatory requirements and submissions, if any, or have fully addressed their primary endpoint(s) before all their participants roll over into this MK-3475-587 extension study.
Criteri di esclusione:
There are no exclusion criteria to participate in MK-3475-587
pembrolizumab+SOC/standard of Care (Per Parent Study)
Trattamento di controllo:
SOC (Per Parent Study)
Obiettivi primari dello studio:
Overall Survival (OS) [Time Frame: Up to approximately 10 years]
OS is defined as the time from randomization or start of study treatment for non-randomized participants (on the parent study) to death due to any cause. Participants without documented death at the time of analysis will be censored at the date of the last follow-up.
Obiettivi secondari dello studio:
1. Duration of Response (DOR) Per Evaluation Criteria Used in the Parent Study [Time Frame: Up to approximately 10 years]
DOR is determined by disease assessment and is defined as the time from the earliest date of qualifying response on the parent study until earliest date of disease progression or death from any cause, whichever comes first based upon investigator assessment. The DOR will be presented.
2. Duration of Complete Response (DOCR) Per Evaluation Criteria Used in the Parent Study [Time Frame: Up to approximately 10 years]
DOCR is determined by disease assessment and is defined as the time from the date of complete response (CR) on the parent study until earliest date of disease progression or death from any cause, whichever comes first based upon investigator assessment. The DOCR will be presented.
3. Serious Adverse Events (SAEs) [Time Frame: Up to approximately 42 months (Up to 90 days after last dose of study treatment)]
A SAE is defined as any untoward medical occurrence that, at any dose: Results in death, Is life-threatening, Requires inpatient hospitalization or prolongation of existing hospitalization, Results in persistent or significant disability/incapacity or Is a congenital anomaly/birth defect. The number of participants who experience a SAE in this study will be presented.
4. Adverse Events of Special Interest (AEOSI) [Time Frame: Up to approximately 40 months (Up to 30 days after last dose of study treatment)]
AEOSI for this study include selected preferred terms from Medical Dictionary for Regulatory Activities (MedDRA) version 20.1 for the following higher-level terms: Pneumonitis, Colitis, Hepatitis, Nephritis, Adrenal Insufficiency, Hypophysitis, Hyperthyroidism, Hypothyroidism, Thyroiditis, Type 1 Diabetes Mellitus, Severe Skin Reactions Including Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN): or If grade 3 or higher, Uveitis, Pancreatitis, Myositis, Guillain-Barre Syndrome, Myocarditis, Encephalitis, Sarcoidosis, Infusion Reactions and Myasthenic Syndrome. The number of participants who experience an AEOSI in this study will be presented.
5. Events of Clinical Interest (ECI) [Time Frame: Up to approximately 40 months (Up to 30 days after last dose of study treatment)]
ECIs for this study include: 1) An overdose of Sponsor's product, that is not associated with clinical symptoms or abnormal laboratory results or 2) An elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) lab value that is ≥3X the upper limit of normal (ULN) and an elevated total bilirubin lab value that is ≥2X ULN and, at the same time, an alkaline phosphatase lab value that is <2X ULN, as determined by way of protocol-specified laboratory testing or unscheduled laboratory testing. The number of participants who experience an ECI in this study will be presented.
Cliniche Humanitas Gavazzeni
Via Gavazzeni 21 - 24125 Bergamo - BG
Ospedale Papa Giovanni XXIII Bergamo
Piazza OMS 1 - 24127 Bergamo - BG
IRCCS A.O.U. San Martino - IST
Largo Rosanna Benzi 10 - 16132 Genova - GE
Istituto Europeo di Oncologia
Via Ripamonti 435 - 20141 Milano - MI
Istituto Clinico Humanitas Rozzano
Via Manzoni 56 - 20089 Rozzano - MI
UO di Oncologia Medica ed Ematologia
Azienda Ospedaliero-Universitaria di Parma
Via Gramsci 14 - 43126 Parma - PR
Centro di Riferimento Oncologico
Via Franco Gallini 2 - 33081 Aviano - PN
IRCCS Candiolo (TO)
St.Provinciale Km 3,95 SP142 - 10060 Candiolo - TO
Azienda Ospedaliera San Camillo Forlanini
Via Portuense 332 - 00149 Roma - RM
Fondazione Policlinico A. Gemelli
Largo Agostino Gemelli 8 - 00168 Roma - RM
Azienda Ospedaliera Universitaria Senese
Viale Bracci 16 - 53100 Siena - SI
Ospedale Le Scotte - UOC Immunoterapia oncologica
AO S. Maria Terni
Via Tristano di Joannuccio 1 - 05100 Terni - TR
Istituto Nazionale Tumori IRCCS Fondazione Pascale
Via Mariano Semmola - 80131 Napoli - NA
Riferimento: Dr. Paolo Ascierto
Numero di iscrizione a registro: 2017-004417-42
Data di inserimento: 11.02.2019
Data di aggiornamento: 29.03.2022
Merck Sharp & Dohme Corp.
Istiuto nazionale dei Tumori IRCCS - Fondazione Pascale, Napoli
Riferimento: Dr. Paolo Ascierto